Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: A randomized, open-label, parallel-group, multi-center study: The DISCOVERY-Beta study

Vascular Health and Risk Management

Volumn 4, Issue 6, 2008, Pages 1407-1416

  Laks, Toivo ^a   Keba, Ester ^b   Leiner, Mariann ^c   Merilind, Eero ^d   Petersen, Mall ^e   Reinmets, Sirje ^f   Väli, Sille ^g   Sööt, Terje ^h   Otter, Karin ^h  

^a North Estonia Regional Hospital   (Estonia)

^b Clinic of Internal Medicine   (Estonia)

^c Mustamäe Family Doctors Centre   (Estonia)

^d Nõmme Family Doctors Centre   (Estonia)

^e Saku Health Centre   (Estonia)

^f Kristiine Family Doctors   (Estonia)

^g Family Doctor Sille Väli ^*  (Estonia)

^h ASTRAZENECA   (United Kingdom)

Author keywords

Hypercholesterolemia; Low density lipoprotein cholesterol; Rosuvastatin; Simvastatin; Statins; Tolerability

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

AGED; CARDIOVASCULAR DISEASES; ESTONIA; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PYRIMIDINES; RISK ASSESSMENT; SIMVASTATIN; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 60249093255     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Binbrek AS, Elis A, Al-Zaibag M, et al; for the DISCOVERY Alpha Study Group. 2006. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: a randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha Study). Curr Ther Res, 67:21-43.
2. Bots AFE, Kastelein JJP. 2005. Achieving lipid goals in real life: the Dutch DISCOVERY Study. Int J Clin Pract, 59:1387-94.
3. Brown WV, Bays HE, Hassmann DR, et al. for the Rosuvastatin Study Group. 2002. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J, 144:1036-43.
4. Coresh J, Kwiterovich PO Jr. 1996. Small, dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implications. JAMA, 276:914-5.
5. Davidson M, Ma P, Stein EA, et al. 2002. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol, 89:268-75.
6. De Backer G, Ambrosioni E, Borch-Johansen K, et al. for the Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. 2003. Europen guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 24:1601-10.
7. de Lorgeril M, Salen P, Martin J-L, et al. 1999. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation, 99:779-85.
8. Estonian Medical Statistics Bureau. 1997. Some facts about health care in Estonia 1992-1996. Tallinn, p 64.
9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2001. JAMA, 285:2486-97.
10. Fonseca FAH, Ruiz A, Silva JM, et al. 2005. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value - an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin, 21:1307-15.
11. Friedewald WT, Levy RI, Fredrickson DS. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18: 499-502.
12. Gotto AM Jr, Grundy SM. 1999. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data: issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. Circulation, 99: E1-E7.
13. Gupta M, Constance C. 2005. Direct statin comparison of LDL-C values: an evaluation of rosuvastatin therapy (DISCOVERY - Canada). [abstract]. Atheroscler Suppl, 6:108.
14. Herregods MC, Daubresse JC, Michel G, et al. 2006. DISCOVERY BELUX: An open-label, randomised, multi-centre, phase IIIb, parallel group study to compare the efficacy and safety of rosuvastatin and atorvastatin in subjects with type IIa and IIb hypercholesterolaemia. Acta Cardiol, 61:235-6.
15. Ito MK, Delucca GM, Aldridge MA. 2001. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease related events. J Cardiovasc Pharmacol Ther, 6:129-35.
16. Jones PH, Davidson MH, Stein EA, et al; for the STELLAR Study Group. 2003. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol, 92:152-60.
17. Knopp RH. 1999. Drug treatment of lipid disorders. N Engl J Med, 341:498-511.
18. Laks T, Tuomilehto J, Jõeste E, et al. 1999. Alarmingly high occurrence and case fatality of acute coronary heart disease events in Estonia: results from the Tallinn AMI register 1991-94. J Int Med, 246:53-60.
19. LaRosa JC, Hunninghake D, Bush D, et al; for the Task Force on Cholesterol Issues, American Heart Association. 1990. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease: a joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Circulation, 81:1721-33.
20. Levine GN, Keaney JF Jr, Vita JA. 1995. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med, 332:512-21.
21. Marques-Vidal P, Ferrario P, Kuulasmaa K, et al; for the WHO MONICA Project. 1999. Quality Assessment of Data on HDL Cholesterol in the WHO MONICA Project. URL:http://www.ktl.fi/publications/monica/hdl/hdlqa.htm.
22. Middleton A, Fuat A. 2006. Achieving lipid goals in real life: the DISCOVERY-UK study. Br J Cardiol, 13:72-6.
23. Olsson AG, Istad H, Luurila O, et al; on behalf of the Rosuvastatin Investigators Group. 2002. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J, 144:1044-51.
24. Pearson TA, Laurora I, Chu H, et al. 2000. The lipid treatment assessment project (L-TAP): a multi-centre survey to evaluate the percentages of dyslipidemic subjects receiving lipid-lowering therapy and achieving low-density lipoprotein goals. Arch Intern Med, 160:459-67.
25. Reddy KS, Yusuf S. 1998. Emerging epidemic of cardiovascular disease in developing countries. Circulation, 97:596-601.
26. Sans S, Kesteloot H, Kromhout D; on behalf of the Task Force. The burden of cardiovascular diseases mortality in Europe. 1997. Task Force of the European Society of Cardiology on cardiovascular mortality and morbidity statistics in Europe. Eur Heart J, 18:1231-48.
27. Schuster H, Barter PJ, Stender S, et al. 2004. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J, 147:705-12.
28. Schuster H. 2003. Rosuvastatin - a high effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10 - 40 mg doses in dyslipidemic patients. Cardiology, 99:126-39.
29. Sleight P. 2003. Current opinions in the management of coronary heart disease. Am J Cardiol, 92 (Suppl):4N-8N.
30. Strandberg TE, Feely J, Sigurdsson EL. 2004. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10mg/d in high-risk adults: A DISCOVERY study. Clin Ther, 26:1821-33.
31. Thaulow E, Erikssen J, Sandvik L, et al. 1993. Initial clinical presentation of cardiac disease in asymptomatic men with silent myocardial ischemia and angiographically documented coronary artery disease (the Oslo Ischemia Study). Am J Cardiol, 72:629-33.
32. Thom TJ. 1989. International mortality from heart disease: Rates and trends. Int J Epidemiol, 18 (Suppl I):20-8.
33. Tunstall-Pedoe H, Kuulasmaa K., Mähönen M, et al. for the WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project. 1999. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet, 353:1547-57.
34. Tunstall-Pedoe H, Kuulasmaa K, Tolonen H, et al. with 64 other contributors for the WHO MONICA Project. 2003. MONICA Monograph and Multimedia Sourcebook. World's largest study of heart disease, stroke, risk factors, and population trends 1979-2002. Geneva: WHO.
35. Vartianen E, Puska P, Pekkanen J, et al. 1994. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. Br Med J, 309:23-7.
36. Wood D, De Backer G, Faegerman O, et al. 1998. Task Force Report: Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on coronary prevention. Eur Heart J, 19:1434-503.
37. Zhu JR, Tomlinson B, Young MR, et al. 2007. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Curr Med Res Opin, 23:3055-68.
38. Zijlstra F, Patel A, Jones M, et al. for the PCAT collaboration. 2002. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J, 23:550-57.